David Dodd, President and CEO of Aeterna Zentaris, commented, ‘The FDA's acceptance of the NDA submission is another significant milestone inside our strategy to commercialize macimorelin acetate while the first approved oral product for AGHD evaluation. We are finalizing our industrial arrange for this exciting new product. We are also seeking to broaden the industrial application of macimorelin acetate in AGHD for make use of linked to traumatic brain damage victims and other developmental areas, which would represent significant benefit to the evaluation of growth hormone deficiency, while presenting further potential revenue growth opportunities for the Company.’..Period and treatment condition had been included as fixed results. Effect sizes reflecting regression adjustments were calculated with the use of Cohen’s d statistic,35 which represents the mean between-group differences standardized by using the baseline pooled standard deviation. Effect sizes are equal to a z rating of a standard regular distribution . All comparisons were prespecified, and all lab tests were two-sided. A P worth of less than 0.05 was considered to indicate statistical significance. Analyses were conducted with the use of Stata software, version 12 . Results Study Participants A complete of 494 females were screened for eligibility . Of the women, 434 fulfilled the inclusion criteria; 7 women with serious suicidality requiring instant assistance by psychosocial IRC and assistants staff weren’t deemed eligible.